Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

844 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA. Emanuel S, et al. Mol Pharmacol. 2004 Sep;66(3):635-47. doi: 10.1124/mol.104.000638. Mol Pharmacol. 2004. PMID: 15322256
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
Ho CY, Ludovici DW, Maharoof US, Mei J, Sechler JL, Tuman RW, Strobel ED, Andraka L, Yen HK, Leo G, Li J, Almond H, Lu H, DeVine A, Tominovich RM, Baker J, Emanuel S, Gruninger RH, Middleton SA, Johnson DL, Galemmo RA Jr. Ho CY, et al. Among authors: johnson dl. J Med Chem. 2005 Dec 29;48(26):8163-73. doi: 10.1021/jm050680m. J Med Chem. 2005. PMID: 16366598
Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
Maroney AC, Marugan JJ, Mezzasalma TM, Barnakov AN, Garrabrant TA, Weaner LE, Jones WJ, Barnakova LA, Koblish HK, Todd MJ, Masucci JA, Deckman IC, Galemmo RA Jr, Johnson DL. Maroney AC, et al. Among authors: johnson dl. Biochemistry. 2006 May 2;45(17):5678-85. doi: 10.1021/bi0524969. Biochemistry. 2006. PMID: 16634649
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
De Corte BL, Kinney WA, Liu L, Ghosh S, Brunner L, Hoekstra WJ, Santulli RJ, Tuman RW, Baker J, Burns C, Proost JC, Tounge BA, Damiano BP, Maryanoff BE, Johnson DL, Galemmo RA Jr. De Corte BL, et al. Among authors: johnson dl. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32. doi: 10.1016/j.bmcl.2004.06.061. Bioorg Med Chem Lett. 2004. PMID: 15380233
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, Galemmo RA Jr, Johnson DL, Maryanoff BE, Damiano BP. Santulli RJ, et al. Among authors: johnson dl. J Pharmacol Exp Ther. 2008 Mar;324(3):894-901. doi: 10.1124/jpet.107.131656. Epub 2007 Dec 14. J Pharmacol Exp Ther. 2008. PMID: 18083913
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
Ghosh S, Santulli RJ, Kinney WA, Decorte BL, Liu L, Lewis JM, Proost JC, Leo GC, Masucci J, Hageman WE, Thompson AS, Chen I, Kawahama R, Tuman RW, Galemmo RA Jr, Johnson DL, Damiano BP, Maryanoff BE. Ghosh S, et al. Among authors: johnson dl. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41. doi: 10.1016/j.bmcl.2004.08.067. Bioorg Med Chem Lett. 2004. PMID: 15501072
844 results